AngioDynamics, Inc. $ANGO Shares Purchased by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP lifted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 253.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,395,430 shares of the medical instruments supplier’s stock after buying an additional 2,435,365 shares during the period. AngioDynamics makes up approximately 2.1% of Divisadero Street Capital Management LP’s portfolio, making the stock its 11th largest position. Divisadero Street Capital Management LP owned about 8.36% of AngioDynamics worth $33,683,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Legal & General Group Plc raised its holdings in AngioDynamics by 279.5% during the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after purchasing an additional 9,098 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of AngioDynamics in the 2nd quarter valued at $139,000. Fox Run Management L.L.C. acquired a new position in shares of AngioDynamics in the 1st quarter valued at $145,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in AngioDynamics by 13.5% in the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,747 shares of the medical instruments supplier’s stock valued at $166,000 after purchasing an additional 1,989 shares during the last quarter. Finally, Integrated Quantitative Investments LLC acquired a new stake in AngioDynamics during the 2nd quarter worth $241,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a report on Friday, November 28th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Insider Activity at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 10,000 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $11.15 per share, with a total value of $111,500.00. Following the purchase, the chief executive officer owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Lawrence T. Weiss purchased 10,000 shares of AngioDynamics stock in a transaction dated Tuesday, October 21st. The stock was acquired at an average cost of $11.81 per share, with a total value of $118,100.00. Following the completion of the acquisition, the senior vice president directly owned 93,597 shares in the company, valued at approximately $1,105,380.57. This trade represents a 11.96% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 20,890 shares of company stock worth $239,532 in the last quarter. 6.00% of the stock is currently owned by insiders.

AngioDynamics Stock Performance

Shares of AngioDynamics stock opened at $13.47 on Monday. The company has a market cap of $554.96 million, a P/E ratio of -17.27 and a beta of 0.49. AngioDynamics, Inc. has a one year low of $6.92 and a one year high of $13.99. The firm has a fifty day moving average of $11.99 and a two-hundred day moving average of $10.59.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02. The business had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The business’s quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, equities analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.